That's 40% premium from the last close. I hope Elanco will not shelf AT-014, and finds a way to deliver it the markets after a full approval. At least, this program is listed on the "best-in-class" Aratana portfolio list.
From Elanco conference call included ADXS promo....
"Lastly, AT-014. This canine osteosarcoma vaccine is a novel immunology approach developed using a vaccine platform delivery system from – licensed from Advaxis. It was granted conditional licensure by the USDA Center for Veterinary Biologics in December of 2017. In a clinical study of 18 own – client-owned dogs with osteosarcoma, the data suggest that vaccine may delay or prevent metastatic disease and may prolong overall survival in the patients."